Development of orally active novel anti-cancer compounds targeting p53
Reference number | |
Coordinator | Aprea AB |
Funding from Vinnova | SEK 1 065 310 |
Project duration | June 2010 - November 2012 |
Status | Completed |
Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.
You're using version {0} of the web browser {1}. This means that the content or functionality of our website may be limited or unavailable. We recommend that you upgrade your browser to optimise your experience of our website.
Development of orally active novel anti-cancer compounds targeting p53
Reference number | 2010-00386 |
Coordinator | Aprea AB |
Funding from Vinnova | SEK 1 065 310 |
Project duration | June 2010 - November 2012 |
Status | Completed |
Last updated 25 November 2019
Reference number 2010-00386